Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion

Drug Category : Array
Conference Category : Array
Lead Author : Lovett-Racke A, Fox E et al.
Published Date : 28/04/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Final%20AAN%20RMS%202017.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top